Abstract:Poly(ADP-ribosyl) ation is a reversible post-translational protein modification implicated in the regulation of a number of biological functions. Whereas an 18 member superfamily of poly(ADP-ribose) polymerase (PARP) enzymes synthesize poly(ADP-ribose) (PAR), a single protein, PAR glycohydrolase (PARG) is responsible for the catabolism of the polymer. PARP-1 accounts for more than 90% of the poly(ADP-ribosyl)ating capacity of the cells. PARP-1 activated by DNA breaks cleaves NAD(+) into nicotinamide and ADP-ribose and uses the latter to synthesize long branching PAR polymers covalently attached to acceptor proteins including histones, DNA repair enzymes, transcription factors and PARP-1. Whereas activation of PARP-1 by mild genotoxic stimuli may facilitate DNA repair and cell survival, irreparable DNA damage triggers apoptotic or necrotic cell death. In apoptosis, early PARP activation may assist the apoptotic cascade [e.g. by stabilizing p53, by mediating the translocation of apoptosis inducing factor (AIF) from the mitochondria to the nucleus or by inhibiting early activation of DNases]. In most severe oxidative stress situations, excessive DNA damage causes over activation of PARP-1, which incapacitates the apoptotic machinery and switches the mode of cell death from apoptosis to necrosis. Besides serving as a cytotoxic mediator, PARP-1 is also involved in transcriptional regulation, most notably in the NF kappaB and AP-1 driven expression of inflammatory mediators. Pharmacological inhibition or genetic ablation of PARP-1 provided remarkable protection from tissue injury in various oxidative stress-related disease models ranging from stroke, diabetes, diabetic endothelial dysfunction, myocardial ischemia-reperfusion, shock, Parkinson's disease, arthritis, colitis to dermatitis and uveitis. These beneficial effects are attributed to inhibition of the PARP-1 mediated suicidal pathway and to reduced expression of inflammatory cytokines and other mediators (e.g. inducible nitric oxide synthase).

ADP-ribosylation: from molecular mechanisms to human disease

[Poly Adenosine Diphosphate-Ribosylation and Neurodegenerative Diseases].

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

Poly‐ADP‐ribosylation dynamics, signaling, and analysis

The expanding universe of PARP1-mediated molecular and therapeutic mechanisms

ADP-ribosylation of RNA and DNA: from in vitro characterization to in vivo function

ADP-ribosylation of DNA and RNA

New Insights into the Roles of NAD+-Poly(ADP-ribose) Metabolism and Poly(ADP-ribose) Glycohydrolase

ADP-ribose hydrolases: biological functions and potential therapeutic targets

The Making and Breaking of Serine-ADP-Ribosylation in the DNA Damage Response

The FHA and BRCT Domains Recognize ADP-ribosylation During DNA Damage Response.

Poly(ADP-ribosyl)ation, Genetic Instability, and Aging

Regulation of PARP1/2 and the tankyrases: emerging parallels

Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases

Uncovering the Invisible: Mono-ADP-ribosylation Moved into the Spotlight

Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies

The world according to PARP

ADP-ribosylation of RNA in mammalian cells is mediated by TRPT1 and multiple PARPs

A Genetically Encoded Sensor for Real-Time Monitoring of Poly-ADP-Ribosylation Dynamics In Vitro and in Cells

The risky business of ADP-ribosylating telomeric DNA

[Poly(ADP-Ribose) Polymerases 1 and 2: Classical Functions and Interaction with New Histone Poly(ADP-Ribosyl)ation Factor HPF1]